Year Founded
1999
Ownership
Private
Employees
~500
Stage
Commercial
Modalities
Prebiotics

Prolacta Bioscience General Information

Company produces human milk-based fortifiers and nutrition products for premature infants. Their products are used in ~40% of Level III and IV NICUs in the US. Clinical studies show 77% reduction in necrotizing enterocolitis compared to cow milk-based fortifiers.

Contact Information

Website
Primary Industry
[ "Life Sciences", "Food & Nutrition", "Biotech" ]
Corporate Office
Monrovia, California
United States

Drug Pipeline

Prolact+ H2MF
Commercial
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 2
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 3
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum

For full access to Prolacta Bioscience's pipeline data

Book a demo

Key Partnerships

Hospital NICUs

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

Prolacta Bioscience Funding

Deal TypeDateAmountStatusStage
Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view Prolacta Bioscience's complete valuation and funding history, request access »

Prolacta Bioscience Investors

Frontier Venture Capital
Investor Type: Venture Capital
Holding: Minority
Health Evolution Partners
Investor Type: Venture Capital
Holding: Minority
Alta Partners
Investor Type: Venture Capital
Holding: Minority
Investor Name
Investor Type
Holding
Investor Name
Investor Type
Holding
You're viewing 3 of 5 investors. Get the full list »